HIV Management Today

The Nuts and Bolts of Implementing HIV Pre-Exposure Prophylaxis (PrEP) in Clinical Settings

An Interview With Antonio E. Urbina, M.D.

In July 2012, the U.S. Food and Drug Administration (FDA) approved, for the first time, an antiretroviral drug for the prevention of HIV. To be specific, the FDA approved the fixed-dose combination pill tenofovir/emtricitabine (Truvada). The drug has existed for years as an HIV treatment option, but the FDA's action this past summer made it the first drug approved for HIV pre-exposure prophylaxis, or PrEP for short.

As we prepare for the introduction of PrEP into clinical settings throughout the U.S., there are understandably a huge number of questions. To address many of these questions and obtain guidance for health care professionals across the clinical spectrum on how to prepare for and adjust to the rollout of PrEP, I spoke by phone with Antonio E. Urbina, M.D., the associate medical director at St. Luke's and Roosevelt Hospital's Center for Comprehensive Care's West 17th Street Clinic in New York City. Prior to that, Urbina was, for many years, the medical director of education and training at St. Vincent's Comprehensive HIV Center.

Antonio E. Urbina, M.D.

Download Audio

Copyright © 2012 Remedy Health Media, LLC. All rights reserved.

Advertisement